Previous 10 |
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer,...
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of Mavacamten’s Effect on Diastolic Function Expected in 2H 2019 from MyoKardia’s MAVERICK-HCM Phase...
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) MyoKardia Management to Host a Conference Call on November 12 at 8:00 a.m. ET to Review Data SOUTH SAN...
At its R&D Day today, MyoKardia ( MYOK +1.2% ) will present the following future milestones: More news on: MyoKardia, Healthcare stocks news, Read more ...
Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy Volunteers Presented; Phase 2a Multiple-ascending Dose Trial Initiated Introduced MYK-224, ACT-1 and LUS-...
First-of-its-kind Digital Platform for HCM Patients Intended to Provide a Powerful Patient Resource to Improve Disease Understanding and Deepen Patient Engagement and Advocacy SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc., (Nasdaq: MYOK), a clinical sta...
The following slide deck was published by MyoKardia in conjunction with this Read more ...
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the fo...
HCM Patients at Greater Risks of Atrial Fibrillation, Heart Failure and Increased Mortality Younger Age of Diagnosis and Genetic Status Associated with Higher Rates of Long-term Complications and Early Death SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE...
News, Short Squeeze, Breakout and More Instantly...
EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten T reatment Resulted in Favorable Effect on Cardiac Structure -- Significantly Reduced Hypertrophy in Patien...
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with ...
BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovas...